BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fiorino G, Sturniolo GC, Bossa F, Cassinotti A, di Sabatino A, Giuffrida P, Danese S. A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis. Cells 2019;8:E523. [PMID: 31151306 DOI: 10.3390/cells8060523] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Fiorino G, Sturniolo GC, Bossa F, Cassinotti A, di Sabatino A, Giuffrida P, Danese S. A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis. Cells 2019;8:E523. [PMID: 31151306 DOI: 10.3390/cells8060523] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
2 Murray A, Nguyen TM, Parker CE, Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2020;8:CD000543. [PMID: 32786164 DOI: 10.1002/14651858.CD000543.pub5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
3 Munoz-Perez E, Gonzalez-Pujana A, Igartua M, Santos-Vizcaino E, Hernandez RM. Mesenchymal Stromal Cell Secretome for the Treatment of Immune-Mediated Inflammatory Diseases: Latest Trends in Isolation, Content Optimization and Delivery Avenues. Pharmaceutics 2021;13:1802. [PMID: 34834217 DOI: 10.3390/pharmaceutics13111802] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Yasutomi E, Hiraoka S, Yamamoto S, Oka S, Hirai M, Yamasaki Y, Inokuchi T, Kinugasa H, Takahara M, Harada K, Kato J, Okada H. Switching between Three Types of Mesalazine Formulation and Sulfasalazine in Patients with Active Ulcerative Colitis Who Have Already Received High-Dose Treatment with These Agents. J Clin Med 2019;8:E2109. [PMID: 31810227 DOI: 10.3390/jcm8122109] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Sadeghi O, Milajerdi A, Siadat SD, Keshavarz SA, Sima AR, Vahedi H, Adibi P, Esmaillzadeh A. Effects of soy milk consumption on gut microbiota, inflammatory markers, and disease severity in patients with ulcerative colitis: a study protocol for a randomized clinical trial. Trials 2020;21:565. [PMID: 32576228 DOI: 10.1186/s13063-020-04523-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
6 Retnakumar SV, Geesala R, Bretin A, Tourneur-Marsille J, Ogier-Denis E, Maretzky T, Thu Nguyen HT, Muller S. Targeting the endo-lysosomal autophagy pathway to treat inflammatory bowel diseases. J Autoimmun 2022;128:102814. [PMID: 35298976 DOI: 10.1016/j.jaut.2022.102814] [Reference Citation Analysis]
7 Awad A, Madla CM, McCoubrey LE, Ferraro F, Gavins FKH, Buanz A, Gaisford S, Orlu M, Siepmann F, Siepmann J, Basit AW. Clinical translation of advanced colonic drug delivery technologies. Adv Drug Deliv Rev 2021;181:114076. [PMID: 34890739 DOI: 10.1016/j.addr.2021.114076] [Reference Citation Analysis]